{
  "id": 518,
  "text": "2023 include: CERV-ESystemicTherapyfor Cervical Cancer-continued CERV-F 1A of 3 ·Footnterevised:standtoxicityeciallywheningextendedfiedshoulbecarfullycnsidered.New footnote c added: These agents may be considered when cisplatin and carboplatin are unavailable.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 2023 include: CERV-ESystemicTherapyfor Cervical Cancer-continued CERV-F 1A of 3 ·Footnterevised:standtoxicityeciallywheningextendedfiedshoulbecarfullycnsidered.New footnote c added: These agents may be considered when cisplatin and carboplatin are unavailable.\n\n<question>: ",
  "ChatGPT_response_0": "若顺铂和卡铂无法获得，2023年的治疗方法中可以考虑使用持续CERV-F 1A的三分之一。这些药物可能作为替代选择，但在应用时应谨慎考虑其毒性和副作用。在选择合适的治疗方案时，建议密切监测患者的反应和疗效，以确保最佳的治疗结果。",
  "query": "2023年的治疗方法包括：对于宫颈癌的系统疗法——持续CERV-F 1A的3分之一。当顺铂和卡铂无法获得时，是否应考虑使用这些药物？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 2023年的治疗方法包括：对于宫颈癌的系统疗法——持续CERV-F 1A的3分之一。当顺铂和卡铂无法获得时，是否应考虑使用这些药物？\n\n<reference text>: 2023 include: CERV-ESystemicTherapyfor Cervical Cancer-continued CERV-F 1A of 3 ·Footnterevised:standtoxicityeciallywheningextendedfiedshoulbecarfullycnsidered.New footnote c added: These agents may be considered when cisplatin and carboplatin are unavailable.\n\n<reply>: ",
  "response": "若顺铂和卡铂无法获得，2023年的治疗方法中可以考虑使用持续CERV-F 1A的三分之一。这些药物可能作为替代选择，但在应用时应谨慎考虑其毒性和副作用。在选择合适的治疗方案时，建议密切监测患者的反应和疗效，以确保最佳的治疗结果。"
}